Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its ...

Regeneron is planning to re-apply to the FDA with a new pre-filled syringe manufacturing filler in January 2026.

Regeneron Pharmaceuticals recently saw its Fair Value price target increased from $722.20 to $735.72. This change comes on ...

Regeneron posts Q3 earnings of $11.83 per share, topping estimates as Dupixent profits lift results despite weaker Eylea ...

Regeneron investors should embrace the fact that Eylea is no longer a growth product and focus on the rest of the commercial ...

Regeneron has once again received a complete response letter (CRL) from the US Food and Drug Administration (FDA) for the ...

Despite the rejection, analysts saw Regeneron’s use of an alternate filler for Eylea HD as a positive development, with BMO Capital Markets noting that this could signal the end of manufacturing ...

The FDA has issued another complete response letter (CRL) to Regeneron, rejecting its bid for approval of its prefilled syringe version of high-dose (HD) Eylea—again for unresolved issues at the ...

Detailed price information for Bayer Aktienges ADR (BAYRY) from The Globe and Mail including charting and trades.

Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its ...

Second-generation anti-VEGF agents, like aflibercept 8 mg and faricimab, show improved efficacy and treatment durability in ...